T. Rowe Price Associates
AURA icon

T. Rowe Price Associates’s Aura Biosciences AURA Stock Holding History

T. Rowe Price Associates’s Portfolio AURA Stock Details AURA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.98M Sell
278,471
-136,720
-33% -$978K ﹤0.01% 2010
2026
Q1 		$2.78M Sell
415,191
-27,598
-6% -$158K ﹤0.01% 1682
2025
Q4 		$2.42M Sell
442,789
-38,442
-8% -$228K ﹤0.01% 1670
2025
Q3 		$2.98M Sell
481,231
-23,597
-5% -$154K ﹤0.01% 1575
2025
Q2 		$3.16M Sell
504,828
-14,957
-3% -$87.5K ﹤0.01% 1451
2025
Q1 		$3.05M Sell
519,785
-37,156
-7% -$281K ﹤0.01% 1422
2024
Q4 		$4.58M Buy
556,941
+40,815
+8% +$384K ﹤0.01% 1313
2024
Q3 		$4.6M Sell
516,126
-57,514
-10% -$493K ﹤0.01% 1321
2024
Q2 		$4.34M Sell
573,640
-21,900
-4% -$160K ﹤0.01% 1263
2024
Q1 		$4.68M Sell
595,540
-64,152
-10% -$532K ﹤0.01% 1232
2023
Q4 		$5.84M Buy
659,692
+2,663
+0.4% +$22.6K ﹤0.01% 1177
2023
Q3 		$5.89M Sell
657,029
-8,499
-1% -$91.4K ﹤0.01% 1149
2023
Q2 		$8.22M Sell
665,528
-45,077
-6% -$482K ﹤0.01% 1103
2023
Q1 		$6.59M Sell
710,605
-28,610
-4% -$297K ﹤0.01% 1123
2022
Q4 		$7.76M Buy
+739,215
New +$9.41M ﹤0.01% 1096

Other funds holding AURA

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.91B AUM 12.68% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
CP
Caligan Partners New York $2.13B AUM 758.65% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
FIS
FCPM III Services Naarden, Netherlands $750M AUM 127.27% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return

T. Rowe Price Associates's AURA Position: Q2 2026 in Review

T. Rowe Price Associates reduced its Aura Biosciences (AURA) stake by 33% in Q2 2026, selling an estimated $978K and leaving 278,471 shares worth $1.98M. The position accounts for ﹤0.01% of the portfolio, ranked #2010.

T. Rowe Price Associates first reported a position in AURA in Q4 2022 and has held it in 15 quarters since. The position peaked at $8.22M in Q2 2023. 146 funds tracked by Wall St. Rank hold AURA as of Q2 2026.

  • T. Rowe Price Associates held 278,471 shares of Aura Biosciences worth $1.98M as of Q2 2026.
  • T. Rowe Price Associates sold 136,720 Aura Biosciences shares in Q2 2026, an estimated $978K.
  • Aura Biosciences made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q2 2026, its #2010 holding.
  • T. Rowe Price Associates first reported a position in Aura Biosciences in Q4 2022 and has held it in 15 quarters since.
  • T. Rowe Price Associates's Aura Biosciences position peaked at $8.22M in Q2 2023.
  • 146 funds tracked by Wall St. Rank held Aura Biosciences as of Q2 2026.

Based on T. Rowe Price Associates's 13F filing for Q2 2026, filed 14 Aug 2026.